Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells

Claudia Terraza-Aguirre, Mauricio Campos-Mora, Roberto Elizondo-Vega, Rafael A. Contreras-López, Patricia Luz-Crawford, Christian Jorgensen, Farida Djouad

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Mesenchymal stem cells (MSCs) exhibit potent immunoregulatory abilities by interacting with cells of the adaptive and innate immune system. In vitro, MSCs inhibit the differentiation of T cells into T helper 17 (Th17) cells and repress their proliferation. In vivo, the administration of MSCs to treat various experimental inflammatory and autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, and bowel disease showed promising therapeutic results. These therapeutic properties mediated by MSCs are associated with an attenuated immune response characterized by a reduced frequency of Th17 cells and the generation of regulatory T cells. In this manuscript, we review how MSC and Th17 cells interact, communicate, and exchange information through different ways such as cell-to-cell contact, secretion of soluble factors, and organelle transfer. Moreover, we discuss the consequences of this dynamic dialogue between MSC and Th17 well described by their phenotypic and functional plasticity.

Original languageEnglish
Article number1665
Issue number7
StatePublished - 10 Jul 2020


  • Th17 cells
  • immunoregulation
  • mesenchymal stem cells


Dive into the research topics of 'Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells'. Together they form a unique fingerprint.

Cite this